

Curriculum Vitae

Name: Iwao Ojima

Title: *University Distinguished Professor*

Education:

1968 B. S. degree	The University of Tokyo
1970 M. S. degree	The University of Tokyo
1973 Ph.D. degree	The University of Tokyo (Prof. Naoki Inamoto)

Appointments:

1973-1983 Senior Research Fellow and Group Leader, Sagami Institute of Chemical Research
 1983 Associate Professor, Department of Chemistry, State University of New York at Stony Brook
 1984 Professor, Department of Chemistry, State University of New York at Stony Brook
 1989 Professeur invité, Université Claude Bernard Lyon I, Lyon, France
 1991 Leading Professor, State University of New York at Stony Brook
 1995 University Distinguished Professor, State University of New York
 1996 Visiting Professor, The University of Tokyo, Tokyo, Japan
 1997 Visiting Professor, The Scripps Research Institute, La Jolla, CA
 1997 Professeur invité, Université de Paris XI, BIOCIS, Châtenay-Malabry, France
 1997-2003 Chairman, Department of Chemistry, State University of New York at Stony Brook
 2003-present, Director, Institute of Chemical Biology and Drug Discovery, Stony Brook.
 2016-present, President, National Academy of Inventors Stony Brook University Chapter.

Award and Honors:

The 25th National Young Investigator Award ("Shimpo Sho"), The Chemical Society of Japan, 1976.
 Arthur C. Cope Scholar Award, the American Chemical Society, 1994.
 The 51st Chemical Society of Japan Award ("Nihon Kagaku Kai Sho") for distinguished achievements, The Chemical Society of Japan, 1999.
 Emanuel B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the American Chemical Society, 2001.
 Outstanding Inventor Award, The Research Foundation of the State University of New York, 2002.
 NYSTAR Faculty Development Award, New York State Office of Science, Technology & Academic Research, 2002.
 Inductee, American Chemical Society, Medicinal Chemistry Hall of Fame, 2006.
 ACS Award for Creative Work in Fluorine Chemistry, the American Chemical Society, 2013.

Fellow, John Simon Guggenheim Memorial Foundation, 1995.
 Fellow, American Association for the Advancement of Science, 1997.
 Fellow, New York Academy of Sciences, 2000.
 Fellow, American Chemical Society, "ACS Fellow", 2010
 Fellow, National Academy of Inventors, "NAS Fellow", 2014.

William and Florence Catacosinos Professor in Cancer Research, Stony Brook Foundation, 1994.
 Leading Professorship, State University of New York at Stony Brook, 1991
 Distinguished Professorship, State University of New York, 1995
 He was invited by the Royal Swedish Academy of Sciences to serve as a nominator for the Nobel prize in chemistry for the years 1990, 1996, 2002, and 2014.
 Eli Lilly Lecturer, University of Kansas-Lawrence, 1990.
 National Science Council Lecturer, Taiwan, 1990.
 J. Clarence Karcher Lecturer, The University of Oklahoma, 1992.
 George Leshner Lecturer, Rensselaer Polytechnic Institute, 1995.
 Boehringer-Ingelheim Distinguished Lecturer, Colorado State University, 1997.
 Weissberger-Williams Lecturer, Eastman Kodak Co., 1997.
 Dr. H. Martin Friedman University Lecturer, Rutgers, State University of New Jersey, 2001.
 Bristol-Meyers Squibb Distinguished Lecturer, Colorado State University, 2002.
 FMC Discovery Chemistry Lecturer, FMC Corporation, 2003.
 J. Clarence Karcher Lecturer, The University of Oklahoma, 2003.

Negishi-Brown Lecturer, Purdue University, 2007.

Ralph A. Raphael Lecturer, University of Glasgow, UK, 2008.

The Sosnovsky Distinguished Lectureship, University of Wisconsin Milwaukee, 2008.

Henry J. Shine Lecturer, Texas Tech University, 2009.

National Science Council Lecturer, Taiwan, 2011.

The Ohdang Lectureship Award, The Pharmaceutical Society of Korea, Korea, 2012.

Distinguished Lectureship in Medicinal Chemistry, University of Minnesota, 2013.

The Ji-Yu Guo Endowment Distinguished Lectureship, Institute of Chemistry and BioMedical Sciences, Nanjing University, 2015

Professional Activities:

(Senior Editor)

Future Medicinal Chemistry (2008-)

(Guest Editor)

2006 Drug Resistant Tuberculosis: A Challenge in Chemotherapy, *Curr. Topics Med. Chem.*

2007 Modern Molecular Approaches to Drug Discovery, *Acc. Chem. Res.*

2007 Modern Natural Products Chemistry in Drug Discovery, *J. Med. Chem.*

2014 In-Silico Drug Design and In-Silico Screening, *Molecules*

2015 New Generation of Microtubule-Interacting Anticancer Agents, *Molecules*

(Advisory Board)

1. Editorial Advisory Board of *Journal of Molecular Catalysis* (1986-1995)

2. Editorial Advisory Board of *Journal of Organic Chemistry* (ACS) (1995-1999)

3. Editorial Advisory Board of *Organometallics* (ACS) (1996-1998)

4. Editorial Advisory Board of *Current Topics in Medicinal Chemistry* (2002-present)

5. Editorial Advisory Board of *Letters in Drug Design & Discovery* (2003-present)

6. Editorial Advisory Board of *Medicinal Chemistry* (2004-present)

7. Editorial Advisory Board of *Bull. Chem. Soc. Jpn* (2005-present)

8. Editorial Advisory Board of *Anti-Cancer Agents in Medicinal Chemistry* (2006-2015)

9. Basic Science Advisory Board member, Stony Brook University Cancer Center (1999-2010).

10. Stony Brook University Research Park Oversight Board (2007-2011).

11. Cell in Motion – CiM, Cluster of Excellence, University of Muenster, Germany (2012-present).

(Symposia and Conferences)

1. Chairperson, The Stony Brook Symposium on Taxol and Taxotère, "New Hope for Breast Cancer Chemotherapy" Stony Brook, NY, May (1993).

2. Chairperson, Symposium on "Recent Advances in the Chemistry of Taxane and Taxoid Anticancer Agents", 207th American Chemical Society National Meeting, San Diego, CA, March (1994).

3. Chairperson, Symposium on "Fluoroamino Acids and Peptides in Medicinal Chemistry", 210th American Chemical Society National Meeting, Chicago, IL, August (1995).

4. Organizer and Chairperson, Symposium on "New Prospects in Anticancer Agents for the 21st Century" 219th American Chemical Society National Meeting, San Francisco, CA, March (2000).

5. Organizer, Ernest Guenther Award Symposium", 219th American Chemical Society National Meeting, San Francisco, CA, March 2000.

6. Organizer, Ernest Guenther Award Symposium, 229th American Chemical Society National Meeting, San Diego, CA, March (2005).

7. Organizer, Symposium on "Drug Resistant Tuberculosis – Challenge in Chemotherapy", 229th American Chemical Society National Meeting, San Diego, CA, March (2005).

8. Organizer, ACS Award in Organometallic Chemistry Symposium, 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).

9. Organizer, "Modern Natural Products Chemistry and Drug Discovery" Symposium, 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).

10. Organizer, "Ernest Guenther Award Symposium, 233rd American Chemical Society National Meeting, Chicago, IL, March (2007).

11. Organizer, "Modern Molecular Strategies for Tumor-Targeting Drug Delivery", 234th American Chemical Society National Meeting, Boston, MA, August (2007)

(Advisory Committee, Panel Reviewer)

1. Advisory Committee Member, NIH, Medicinal Chemistry (MCHA) Study Section (1988-1992).

2. Ad Hoc Member, Triennial Oversight Committee, Chemistry Division, NSF (1992).

3. Panel Reviewer, Basic Energy Science Program, U. S. Department of Energy (1992).
4. Advisory Committee Member Reserve, NIH (1992-1995).
5. Panel Reviewer, REU Program, Chemistry Division, NSF (1992).
6. Panel Reviewer, NSF Postdoctoral Fellowship in Chemistry (1994).
7. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1995).
8. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1995).
9. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1996).
10. Chemistry and Related Sciences Special Emphasis Panel, NIH, SBIR and STTR Programs (1996).
11. Panel Reviewer, NSF Small Business Innovation Research (SBIR) Program (1997).
12. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1998).
13. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (2001).
14. Special Panel Reviewer, NIH, Bioorganic and Natural Product Chemistry (BNP) Study Section (2002).
15. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2002).
16. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2003).
17. Panel Reviewer, NIH, Drug Discovery & Molecular Pharmacology (DMP) Study Section, Oncological Sciences IRG (2004).
18. Panel Reviewer, NCI, National Cooperative Drug Discovery Groups for Cancer (NCDDG) IRG (2004).
19. Special Emphasis Panel Reviewer, NCI, ONC-K Study Section (2005).
20. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (2005).
21. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (AIR, AED) (Feb. and July 2008)
22. Panel Reviewer, NIH, Synthetic and Biological Chemistry A (SBCA) Study Section (June 2009)
23. Special Emphasis Panel Reviewer, NIH Challenge Grant (June 2009)
24. Panel Reviewer, NIH, SBIR/STTR Cancer Drug Development Study Section (July 2009)
25. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (September 2010)
26. Special Emphasis Panel Reviewer, NIH, NIAID Biodefense Study Section (October 2011)
27. Panel Reviewer, NCI, SBIR Contract, Development of Anticancer Agents Study Section (March 2012)
28. Special Emphasis Panel Reviewer, NIH, NIAID Biodefense Study Section (September 2012)
29. Special Emphasis Panel Reviewer, NIH, NCI, SBIR Bridge Award Study Section (June 2013)
30. Special Emphasis Panel Reviewer, NIH, NIAID, CETR Study Section (July/September 2013)
31. Special Emphasis Panel Reviewer, NIH, NCI, OTC Cancer Therapeutics Study Section (January 2014)
32. Research Grants Council of Hong Kong (May 2015)
33. Reviewer, Defense Threat Reduction Agency (DTRA), Fundamental Research to Counter Weapons of Mass Destruction Program (October 2015)
34. Reviewer, Research Council of Norway (October 2015)
35. Reviewer, Oakridge Associated Universities, Florida Department of Health (December 2015)
36. Reviewer, Defense Threat Reduction Agency (DTRA), Fundamental Research to Counter Weapons of Mass Destruction Program (May 2016)
37. Reviewer, Research Corporation for Science Advancement (October 2016)

(American Chemical Society)

1. Executive Committee Member, Division of Organic Chemistry, American Chemical Society (1998-2001).
2. Long Range Planning Committee, Division of Medicinal Chemistry, American Chemical Society (2003-2006).

Consulting:

He has served as a consultant for E. I. du Pont, Eli Lilly, Air Products & Chemicals, Mitsubishi Chem. Corp, Nippon Steel Corp. Life Science Division, Rhone-Poulenc Rorer, ImmunoGen, Inc., Taiho Pharmaceutical Co., Milliken & Co., Aventis Pharma, OSI Pharmaceuticals, Inc., INDENA, SpA, Day Casebeer LLP, Fujian Yew Park Biological Co., Ltd., ChemMaster International, Central Glass Co., Ajinomoto Co., Inc. (current), Tayler Wessing LLP (current), Guidepoint Global Advisors (current), Fitzpatrick, Cella, Harper & Scinto (current), Quinn Emanuel Urquhart & Sullivan, LLP (current).

Memberships

He is a member of American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Peptide Society, New York Academy of Sciences, Sigma Xi, The Chemical Society of Japan, and The Society of Synthetic Organic Chemistry, Japan.

Research Interest and Activities:

His research interests include drug design and discovery (anticancer agents, antibacterial agents, enzyme inhibitors), medicinal chemistry and chemical biology, catalytic asymmetric synthesis, organic synthesis by means of organometallic reagents and catalysts, homogeneous catalysis and organometallic chemistry, peptide and peptidomimetics, β -lactam chemistry, and organofluorine chemistry (fluoroamino acids and peptides, fluorotaxoids, medicinal applications). He has published more than 450 papers and reviews in leading journals and more than 100 patents granted, edited 8 books, and he has given 130 Plenary and Invited Lectures in international conferences and symposia by August 2016. SciFinder lists more than 980 publications to his credit. Google Scholar shows his h-index as 69 and total citation of >22,000 by September 2016. He has also given numerous invited lectures at universities, research institutes, and industries (total >500 since his move to Stony Brook in 1983).

Educational Activity as Thesis and Research Advisor:

He has advised 66 postdoctoral research associates/fellows, 113 graduate students (65 Ph.D. degrees and 34 M.S. degrees), 95 undergraduate research students, 12 visiting scientists, and 55 high school summer research students (most of them won Intel and Siemens Science Competitions, including Grand Prize) by August 2016.

Selected Plenary and Invited Lectures in International Meetings since 2010:

- 107 Perugia Fluorine Days: Organofluorine Compounds in Biomedical and Agricultural Sciences, Perugia, Italy, July 11-15, 2010. "Medicinal Chemistry and Chemical Biology of Fluorine-Containing Taxoid Anticancer Agents".
- 108 11th Eurasia Conference on Chemical Sciences (EuAsC₂S-11), The Dead-Sea, Jordan, October 6-10, 2010. "Tumor-Targeting Drug Delivery of Chemotherapeutic Agents".
- 109 10th Tateshina Conference on Organic Chemistry, Tateshina, Japan, November 12-14, 2010. "Chemistry and Chemical Biology of Tumor-Targeting Anticancer Agents".
- 110 2nd World Congress on Catalytic Asymmetric Synthesis (WCCAS-2011), Beijing, China, August 9-11, 2011. "Catalytic Asymmetric Synthesis with Novel Biphenol-Based Chiral Ligands".
- 111 2nd International Conference of Medicchem (ICM-2011), Beijing, China, August 9-11, 2011. "Design and Development of "Guided Molecular Missiles" for Tumor-Targeting Chemotherapy".
- 112 12th Conférence Universitaire de Suisse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "Synthetic Organic Chemistry at the Biomedical Interface".
- 113 12th Conférence Universitaire de Suisse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "New Strategy for the Rapid Construction of Fused Ring Systems of Biological Interest".
- 114 12th Conférence Universitaire de Suisse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "Catalytic Asymmetric Synthesis with Novel Biphenol-Based Phosphorus Ligands".
- 115 International Research Training Group (IRTG) Mini-Symposium, Münster, Germany, November 11, 2011. "Synthetic Organic Chemistry at the Biomedical Interface".
- 116 3rd International Symposium on Organofluorine Compounds in Biomedical, Materials and Agricultural Sciences, Valencia, Spain, May 20-24, 2012. "Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery".
- 117 International Convention of The Pharmaceutical Society of Korea, Seoul, Korea, October 23-24, 2012. "Tumor-Targeting Drug Delivery of Chemotherapeutic Agents".
- 118 International Drug Discovery Science and Technology Conference, Nanjing, China, November 8-10, 2012. "Targeting Prostate, Colon and Breast Cancer Stem Cells with New Generation Taxoids".
- 119 International Symposium of Drug Delivery Systems, Nanjing, China, November 8-10, 2012. "Tumor-Targeting Drug Conjugates of New Generation Taxoids".
- 120 21st Winter Fluorine Conference, American Chemical Society, St. Petersburg, FL, January 13-18, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface in Perspective - A Personal Account".
- 121 245th American Chemical Society National Meeting, New Orleans, LA, April 9-12, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface".
- 122 International Fluorine Workshop, Tokyo, Japan, April 13-14, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface in Perspective".
- 123 Congress of International Drug Discovery Science & Technology, Therapy and EXPO, Haikou, China, November 13-16, 2013. "New Generation Antibacterial Drug Discovery Targeting Bacterial Cell Division".
- 124 Congress of International Drug Discovery Science & Technology, Therapy and EXPO, Haikou, China, November 13-16, 2013. "New Generation Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery".

- 125 4th International Symposium on Organofluorine Compounds in Biomedical, Materials and Agricultural Sciences, “Bordeaux Fluorine Days”, Bordeaux, July 6-10, 2014. “Strategic Incorporation of Fluorine into Novel Anti-TB Agents and Anticancer Drug Conjugates for Preclinical Drug Development”.
- 126 248th American Chemical Society National Meeting, San Francisco, CA, August 10-14, 2014. “New Generation Anti-TB Drug Discovery Targeting *Mtb*-FtsZ”.
- 127 International Symposium of Chemistry and Life Sciences, Jiangyin China, October 16-17, 2014. “Tumor-Specific Guided Molecular Missiles for Next Generation Cancer Chemotherapy”.
- 128 DFG-GRK “Fluorine as a Key Element” Workshop, Berlin, Germany, April 23-24, 2015. "Strategic Incorporation of Fluorine into Bioactive Compounds for Medicinal Chemistry and Chemical Biology Studies - Part I"; "Strategic Incorporation of Fluorine into Bioactive Compounds for Medicinal Chemistry and Chemical Biology Studies - Part II".
- 129 21st International Symposium on Fluorine Chemistry, Como, Italy, August 23-28, 2015. “Strategic Incorporation of Fluorine into Novel Tumor-Targeting Drug Conjugates for Preclinical Development Using ¹⁹F NMR and PET imaging”.
- 130 5th International Symposium on Organofluorine Compounds in Biomedical, Organic Materials and Agriculture Sciences, “Bremen Fluorine Days”, Bremen, Germany, July 3-7, 2016.

Invited Lectures Since 2010:

- 448 The Tosoh Organic Synthesis Seminar, Odaiba, Tokyo, Japan [April 22, 2010, K. Kato]
- 449 Ajinomoto Pharmaceutical Co. Ltd., Pharmaceutical Research Laboratory, Kawasaki, Japan [Nov. 4, 2010, K. Sakurai, T. Tsuji]
- 450 Kitasato Institute and Kitasato University, Sirogane, Tokyo, Japan [Nov. 5, 2010, T. Sunazuka, S. Omura]
- 451 Shonan High School, Fujisawa, Japan [Nov. 6, 2010, M. Kato, A. Komuro]
- 452 Central Glass KK, Chemical Research Center, Kawagoe, Japan [Nov. 8, 2010, Y. Hibino]
- 453 The University of Tokyo, Graduate School of Pharmaceutical Science, Hongo, Tokyo, Japan [Nov. 9, 2010, T. Fukuyama]
- 454 Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences, Baltimore, MD [March 2, 2011, J. Liu]
- 455 Colorado State University, Department of Microbiology, Immunology and Pathology, Fort Collins, CO [June 27, 2011, R A. Slayden]
- 456 National Chiao-Tung University, Department of Chemistry, Hsin-Chu, Taiwan [August 1, 2011, C.-M. Sun]
- 457 National Health Research Institutes, Zhu-Nan, Taiwan [August 2, 2011, H.-P. Hsieh]
- 458 National Chung Cheng University, Department of Chemistry and Biochemistry, Chia-Yi, Taiwan [August 3, H.-J. Chen]
- 459 National Taiwan University, Department of Chemistry, Taipei, Taiwan [August 5, T-Y. Luh]
- 460 Pharmaron Beijing, Beijing, China [August 8, 2011, B. Lou, H. Yang, J. Wei]
- 461 Swiss Federal Institute of Technology (ETH), Institute of Pharmaceutical Sciences, Zurich, Switzerland [September 2, 2011, K.-H. Altmann]
- 462 Sanofi-Aventis, Division of Infectious Diseases, Toulouse, France [September 6, 2011, L. Fraisse, G. Courtemanche]
- 463 The University of Tokyo, Graduate School of Engineering, Tokyo, Japan [October 24, 2011, M. Fujita]
- 464 Keio University, Department of Chemistry, Yokohama, Japan [October 26, 2011, T. Yamada]
- 465 Central Glass Co. Ltd., Chemical Research Center, Saitama, Japan [October 27, 2011, T. Kume, Y. Hibino]
- 466 Ajinomoto Pharmaceuticals, Co., Ltd., Pharmaceutical Research Center, Kawasaki, Japan [October 31, T. Tsuji, K. Sakurai]
- 467 Hamari Chemicals Ltd., Osaka, Japan [November 7, 2011, T. Takami, H. Moriwaki]
- 468 Kitasato Institute and University, Tokyo, Japan [January 18, 2012, T. Sunazuka]
- 469 RIKEN, Advanced Science Institute, Saitama, Japan [January 19, 2012, Z. Hou]
- 470 Kanagawa University, Faculty of Science, Department of Chemistry, Kanagawa, Japan [January 20, 2012, M. Matsumoto]
- 471 University of Barcelona, Institute of Organic Chemistry, Barcelona, Spain [May 25, 2012, J. Garcia Gomez]
- 472 University of Ikerbasque, Department of Chemistry, San Sebastian, Spain [May 29, 2012, V. Soloshonok]
- 473 Centro de Investigaciones Biológicas (CIB), National Research Council (CSIC), Madrid, Spain [June 1, 2012, J. F. Diaz Pereira]
- 474 Department of Chemistry, Xiamen University, Xiamen, China [June 21, 2012, Y. Zhao]
- 475 Haikou Municipal Hospital and Central South University School of Medicine, Haikou, Hainan, China [June 23, 2012, G. Tian]
- 476 Chungnam National University, College of Pharmacy, Daejeon, Korea [October 24, 2012, S.-H. Jung]

- 477 The University of Tokyo, Department of Applied Chemistry, Tokyo, Japan [October 30, 2012, M. Fujita]
478 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [October 31, 2012, T. Tsuji, K. Sakurai]
479 Central Glass Co. Ltd., Chemical Research Center, Kawagoe, Japan [November 1, 2012, Y. Ishi, M. Fujiwara]
480 Shanghai Institute of Materia Medica, Shanghai, China [November 16, 2012, H. Liu]
481 University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN [September 17, 2013, C. Haskell-Luevano]
482 Rutgers, State University of New Jersey, College of Pharmacy, New Brunswick, NJ [September 24, 2013, E. Lavoie]
483 The University of Tokyo, Graduate School of Chemistry, Tokyo, Japan [November 5, 2013, E. Nakamura]
484 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [November 7, 2013, K. Sakurai]
485 Central Glass Co. Ltd., Chemical Research Center, Kawagoe, Japan [November 8, 2013, T. Komata]
486 Guangzhou Institutes of Biomedicine and Health, Drug Discovery Pipeline, Guangzhou, China [November 18, 2013, M. Tortorella]
487 Guangzhou Institutes of Biomedicine and Health, Guangzhou, China [November 19, 2013, Ding Ke, M. Tortorella]
488 Sundia MediTech, Shanghai, China [November 21, 2013, J. Zhu]
489 Ecole Polytechnique, Université Paris-Saclay, Palaiseau, France [July 15, 2014, S. Zard]
490 Gakushuin University, Department of Chemistry, Mejiro, Tokyo, Japan [September 24, 2014, T. Akiyama]
491 Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan [September 25, 2014, Y. Hayashi].
492 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [October 29, 2014, K. Sakurai]
493 Central Glass Co., Ltd., Chemical Research Center, Kawagoe, Japan [October 30, 2014, T. Komata]
494 Kitasato Institute and Kitasato University Graduate School, Sirogane, Tokyo, Japan [Nov. 5, 2014, T. Sunazuka]
495 The University of Tokyo, Graduate School of Pharmaceutical Sciences, Hongo, Tokyo, Japan [Nov. 6, 2014, M. Kanai]
496 Kyoto University, Department of Synthetic and Biological Chemistry, Katsura, Kyoto, Japan [Nov. 8, 2014, M. Murakami]
497 Queens College – City University of New York, Department of Chemistry and Biochemistry, Queens, New York [March 16, 2015, H. Gafney, Y. Chen]
498 Institute of Chemistry and BioMedical Sciences, Nanjing University, Nanjing, China [July 21, 2015, G. Li]
499 Shanghai Jian-Tong University, School of Chemistry and Chemical Engineering, Shanghai, China [July 23, W. Zhang]
500 Daiichi Sankyo, Co. Ltd., Drug Discovery Chemistry Research Center, Shinagawa, Tokyo, Japan [Oct. 26, M. Nagamochi]
501 Central Glass Co., Ltd., Chemical Research Center, Kawagoe, Japan [Oct. 29, 2015, M. Yasumoto]
502 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [Oct. 30, 2015, M. Tokumasu]
503 The University of Tokyo, Graduate School of Chemistry, Hongo, Tokyo, Japan [Nov. 6, 2015, H. Suga]
504 RIKEN, Advanced Science Institute, Wako, Saitama, Japan [Oct. 18, 2016, M. Sodeoka]
505 Kitasato Institute and Kitasato University Graduate School, Sirogane, Tokyo, Japan [Oct. 24, 2016, T. Sunazuka]
506 Central Glass Co., Ltd., Chemical Research Center, Kawagoe, Japan [Oct. 27, 2016, A. Ishii]
507 Ajinomoto, Co., Inc., Research Center, Kawasaki, Japan [Oct. 28, Y. Tanaka]
508 The University of Tokyo, Graduate School of Applied Chemistry, Hongo, Tokyo, Japan [Nov. 2, 2016, M. Fujita]

In addition to these invited lectures, he and his laboratory members regularly present papers at the American Chemical Society's National Meetings, ACS Winter Fluorine Conference, American Association for Cancer Research (AACR) Annual Meeting.